Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: Results of the Dyslipidaemia International Study

Diabetic Medicine

Volumn 28, Issue 11, 2011, Pages 1343-1351

  Leiter, L A ^a   Lundman, P ^b   da Silva, P M ^c   Drexel, H ^d   Junger C ^e   Gitt, A K ^e  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b KAROLINSKA INSTITUTE   (Sweden)

^c HOSPITAL DE SANTA MARTA   (Portugal)

^d Vorarlberg Institute for Vascular Investigation and Treatment VIVIT   (Austria)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cardiovascular disease; Diabetes mellitus; Dyslipidaemia; Metabolic syndrome; Statins

Indexed keywords

CHOLESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CANADA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG DOSE TITRATION; DRUG POTENCY; DYSLIPIDEMIA; EUROPE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; PRACTICE GUIDELINE; PREVALENCE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTICHOLESTEREMIC AGENTS; CANADA; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; EUROPE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; METABOLIC SYNDROME X;

EID: 80054682430     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03360.x     Document Type: Article

References (25)

1. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al. ; CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
2. Cholesterol Treatment Trialists' (CTT) Collaborators. Cholesterol-lowering treatment in 18686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-125.
3. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2008; 32: S1-S201.
4. Grundy SM, Cleeman JI, Merz CN, Brewer HS Jr, Clark LT, Hunninghake DB et al. ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment PanelIII guidelines. Circulation 2004; 110: 227-239.
5. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007; 28: 2375-2414.
6. Kotseva K, Wood D, de Backer G, de Bacquer D, Pylorala K, Keil U et al. ; EUROASPIREIII Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIREI, II, and III surveys in eight European countries. Lancet 2009; 373: 929-940.
7. Alexander CM, Landsman PB, Teutsch SM, Haffner SM, Third National Health and Nutrition Survey (NHANESIII), National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes and the prevalence of coronary heart disease among NHANESIII participants age 50years and older. Diabetes 2003; 52: 1210-1214.
8. Gitt AK, Drexel H, Feely J, Ferrières J, Gonzalez-Juanatey JR, Thomsen KK et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Cardiovasc Prev Rehabil. 2011; in press. DOI: .
9. International Diabetes Federation. The IDF Worldwide Definition of the Metabolic Syndrome. Brussels: IDF Communications; 2006. Available at Last accessed 9 January 2011.
10. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-213.
11. Fodor JG, McPherson R, Dafoe WA, Grenville A. Investigation and treatment of hypercholesterolemia and other dyslipidemias in Canadian primary care practice. CVD Prevent 1998; 1: 225-230.
12. Hackam DG, Tan MK, Honos GN, Leiter LA, Langer A, Goodman SG; Vascular Protection Registry Investigators. How does the prognosis of diabetes compare with that of established vascular disease? Insights from the Canadian Vascular Protection (VP) Registry. Am Heart J 2004; 148: 1028-1033.
13. Yan AT, Yan RT, Tan M, Hackam DG, Leblanc KL, Kertland H et al. Vascular Protection (VP) and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries Investigators. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006; 119: 676-683.
14. Bourgault C, Davignon J, Fodor G, Gagné C, Gaudet D, Genest J et al. Statin therapy in Canadian patients with hypercholesterolemia: The Canadian Lipid Study - Observational (CALIPSO). Can J Cardiol 2005; 21: 1187-1193.
15. Foley KA, Simpson RJ Jr, Crouse JR 3rd, Weiss TW, Markson LE, Alexander CM. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003; 92: 79-81.
16. Berthold HK, Gouni-Berthold I, Bestehorn K, Bohm M, Krone W. Cardiovascular risk factors in patients with type2 diabetes in Germany. Dtsch Artbl 2007; 104: A861-A867.
17. Braga MFB, Casanova A, Teoh H, Dawson KG, Gerstein HC, Fitchett DH et al. ; Diabetes Registry to Improve Vascular Events (DRIVE) Investigators. Treatment gaps in the management of cardiovascular risk factors in patients with type2 diabetes. Can J Cardiol 2010; 26: 297-302.
18. Drexel H, Aczel S, Marte T, Vonbank A, Saely CH. Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis. Atherosclerosis 2010; 208: 484-489.
19. Bruckert E, Baccara-Dinet M, Eschwege E. Low HDL-cholesterol is common in European type2 diabetic patients receiving treatment for dyslipidemia: data from a pan-European survey. Diabet Med 2007; 24: 388-391.
20. Grant RW, Meigs JB. Prevalence and treatment of low HDL cholesterol among primary care patients with type2 diabetes: an unmet challenge for cardiovascular risk reduction. Diabetes Care 2007; 30: 479-484.
21. Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC Jr. Scientific evidence underlying the ACC/AHA clinical practice guidelines. J Am Med Assoc 2009; 301: 831-841.
22. Robinson JG, Want S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease. J Am Coll Cardiol 2009; 53: 316-322.
23. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotopic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005; 46: 1855-1862.
24. Jafri H, Alsheikh-Ali AA, Richard H, Karas RH. Meta-analysis: Statin therapy does not alter the association between low levels of high-density lipopotein cholesterol and increased cardiovascular risk. Ann Intern Med 2010; 153: 800-808.
25. Ginsberg HN, Elam MB, Lorato LC, Crouse JR 3rd, Leiter LA, Linz P et al. ; ACCORD Study Group. Effects of combination lipid therapy in type2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574.